Daniel Iazzetti was Appointed as Vice President of Human Resources at Angion

Date of management change: October 21, 2019 

What Happened?

Uniondale, NY-based Angion Appointed Daniel Iazzetti as Vice President of Human Resources


About the Company

Angion Biomedica Corp. is a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion`s lead product candidate, ANG-3777, is a small molecule designed to mimic the biological activity of hepatocyte growth factor (HGF) to activate the HGF/c-Met pathway, which has a central role in tissue repair and organ recovery. Enrollment is ongoing in a placebo-controlled Phase 3 registration trial examining the efficacy of ANG-3777 in reducing the severity of transplant-associated acute kidney injury, also known as delayed graft function, in patients at risk for kidney dysfunction. ANG-3777 is also in a Phase 2 clinical trial for the treatment of acute kidney injury associated with cardiac surgery involving cardiopulmonary bypass. Angion is also developing ANG-3070, an orally-bioavailable small molecule, as a potential treatment for a variety of chronic fibrotic diseases sharing similar underlying disease-driving pathways identified and targeted using a precision-medicine approach.


About the Person

Daniel Iazzetti is Vice President of Human Resources at Angion. Previously, Daniel held various senior HR leadership roles in the industry.


Info Source



Other IT executives who recently changed jobs as well: Wilson Charlie, Vinci Donald, Brown Tony, Sundaram Mallik, Scovin Sue, Wagner L William, Kautzman John, Goodman Andrew, McElroy Drew, Engelke Valerie, Hulse Mike

You can find the full directory of IT executives here.

How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.